Table of Content

1 INTRODUCTION 33
1.1 STUDY OBJECTIVES 33
1.2 MARKET DEFINITION 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS & REGIONS COVERED 34
1.3.2 INCLUSIONS & EXCLUSIONS 35
1.3.3 YEARS CONSIDERED 35
1.3.4 CURRENCY CONSIDERED 36
1.4 STAKEHOLDERS 36
1.5 SUMMARY OF CHANGES 36
2 RESEARCH METHODOLOGY 38
2.1 RESEARCH DATA 38
2.1.1 SECONDARY DATA 38
2.1.1.1 Key data from secondary sources 39
2.1.2 PRIMARY DATA 40
2.1.2.1 Primary research objectives 40
2.1.2.2 Key data from primary sources 41
2.1.2.3 Key industry insights 42
2.1.2.4 Breakdown of primary interviews 42
2.2 MARKET SIZE ESTIMATION 44
2.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS) 44
2.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS 45
2.2.3 TOP-DOWN APPROACH: SUPPLY-SIDE ANALYSIS 46
2.3 DATA TRIANGULATION AND MARKET BREAKDOWN 49
2.4 MARKET SHARE ESTIMATION 50
2.5 STUDY ASSUMPTIONS 50
2.6 RESEARCH LIMITATIONS 51
2.6.1 METHODOLOGY-RELATED LIMITATIONS 51
2.6.2 SCOPE-RELATED LIMITATIONS 51
2.7 RISK ASSESSMENT 51
3 EXECUTIVE SUMMARY 52
4 PREMIUM INSIGHTS 56
4.1 RESPIRATORY DIAGNOSTICS MARKET OVERVIEW 56
4.2 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET,
BY PRODUCT & SERVICE AND COUNTRY (2023) 57
?
4.3 RESPIRATORY DIAGNOSTICS MARKET: REGIONAL MIX 58
4.4 RESPIRATORY DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 58
5 MARKET OVERVIEW 59
5.1 INTRODUCTION 59
5.2 MARKET DYNAMICS 59
5.2.1 DRIVERS 60
5.2.1.1 Increasing incidence of respiratory disorders 60
5.2.1.2 Expanding geriatric population and rise in sedentary lifestyles 61
5.2.1.3 Growing awareness about respiratory health 61
5.2.1.4 Advancements in diagnostic technologies 62
5.2.2 RESTRAINTS 62
5.2.2.1 High cost of diagnostic tests 62
5.2.2.2 Limited reimbursements 63
5.2.2.3 Shortage of skilled professionals 63
5.2.3 OPPORTUNITIES 63
5.2.3.1 High growth potential of emerging economies 63
5.2.3.2 Increasing demand for POC testing 64
5.2.3.3 Growing awareness about untreated OSA 64
5.2.4 CHALLENGES 66
5.2.4.1 Complexities associated with diagnosis of viral respiratory infections 66
5.2.4.2 Limited access to peripheral lung lesions in bronchoscopy 66
5.3 INDUSTRY TRENDS 67
5.3.1 POINT-OF-CARE TESTING 67
5.3.2 PERSONALIZED MEDICINE 67
5.4 TECHNOLOGY ANALYSIS 68
5.4.1 KEY TECHNOLOGIES 68
5.4.1.1 Home-based & personal DHTs 68
5.4.1.2 PFT tools and molecular & imaging diagnostics 68
5.4.2 COMPLEMENTARY TECHNOLOGIES 69
5.4.2.1 AI-enhanced imaging 69
5.4.2.2 Serological & telehealth platforms 69
5.4.3 ADJACENT TECHNOLOGIES 69
5.4.3.1 Rapid respiratory diagnostic tests 69
5.5 PORTER’S FIVE FORCES ANALYSIS 70
5.5.1 THREAT OF NEW ENTRANTS 71
5.5.2 THREAT OF SUBSTITUTES 71
5.5.3 BARGAINING POWER OF SUPPLIERS 71
5.5.4 BARGAINING POWER OF BUYERS 71
5.5.5 INTENSITY OF COMPETITIVE RIVALRY 71
?
5.6 REGULATORY ANALYSIS 72
5.6.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
5.6.2 REGULATORY LANDSCAPE 75
5.6.2.1 North America 75
5.6.2.1.1 US 75
5.6.2.1.2 Canada 76
5.6.2.2 Europe 77
5.6.2.3 Asia Pacific 77
5.6.2.3.1 India 77
5.6.2.3.2 China 77
5.6.2.3.3 Japan 78
5.6.2.4 Latin America 79
5.6.2.5 Middle East & Africa 79
5.7 PATENT ANALYSIS 79
5.7.1 KEY PATENTS GRANTED 81
5.8 TRADE ANALYSIS 82
5.8.1 IMPORT DATA FOR HS CODE 901819 82
5.8.2 EXPORT DATA FOR HS CODE 901819 83
5.9 PRICING ANALYSIS 83
5.9.1 AVERAGE SELLING PRICE OF RESPIRATORY DIAGNOSTIC PRODUCTS,
BY KEY PLAYER (2024) 84
5.9.2 AVERAGE SELLING PRICE TREND OF RESPIRATORY DIAGNOSTIC PRODUCTS,
BY REGION, 2021–2023 85
5.10 VALUE CHAIN ANALYSIS 86
5.11 KEY STAKEHOLDERS & BUYING CRITERIA 87
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 87
5.11.2 KEY BUYING CRITERIA 88
5.12 KEY CONFERENCES & EVENTS, 2024–2025 89
5.13 UNMET NEEDS/END-USER EXPECTATIONS 89
5.14 ADJACENT MARKET ANALYSIS 90
5.15 ECOSYSTEM ANALYSIS 91
5.16 CASE STUDY ANALYSIS 93
5.17 SUPPLY CHAIN ANALYSIS 94
5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 96
5.19 INVESTMENT & FUNDING SCENARIO 97
5.20 REIMBURSEMENT SCENARIO 97
5.21 IMPACT OF AI/GENERATIVE AI ON RESPIRATORY DIAGNOSTICS MARKET 99
6 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 100
6.1 INTRODUCTION 101
6.2 INSTRUMENTS & DEVICES 101
6.2.1 INTRODUCTION OF AUTOMATED & HIGH-THROUGHPUT INSTRUMENTS
TO DRIVE MARKET 101
6.3 ASSAYS & REAGENTS 103
6.3.1 INCREASING DEMAND FOR RESPIRATORY DIAGNOSTIC TEST KITS TO PROPEL MARKET 103
6.4 SERVICES & SOFTWARE 104
6.4.1 INCREASING DEMAND FOR CONSISTENT UPGRADES AND SUPPORT SERVICES TO FUEL MARKET 104
7 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE 106
7.1 INTRODUCTION 107
7.2 MECHANICAL TESTS 107
7.2.1 PULMONARY FUNCTION TESTS 109
7.2.1.1 Spirometry 111
7.2.1.1.1 Diagnosis of COPD and pulmonary fibrosis to drive market 111
7.2.1.2 Peak flow tests 113
7.2.1.2.1 Ability to provide accurate lung function monitoring with non-invasiveness benefits to fuel uptake 113
7.2.1.3 Other pulmonary function tests 115
7.2.2 OBSTRUCTIVE SLEEP APNEA DIAGNOSTIC TESTS 117
7.2.2.1 Large presence of untreated population to drive market 117
7.2.3 OTHER MECHANICAL TESTS 118
7.3 IMAGING TESTS 120
7.3.1 X-RAY 121
7.3.1.1 Integration of AI into X-ray devices for enhanced imaging capabilities
to drive market 121
7.3.2 COMPUTED TOMOGRAPHY 122
7.3.2.1 Rising focus on obtaining high-resolution CT images to boost demand 122
7.3.3 MAGNETIC RESONANCE IMAGING (MRI) 123
7.3.3.1 Ability to provide detailed lung images without radiation exposure
to drive market 123
7.3.4 POSITRON EMISSION TOMOGRAPHY (PET) 125
7.3.4.1 Growing focus on detection & monitoring of treatment response to lung cancer to drive market 125
7.3.5 OTHER IMAGING TESTS 126
7.4 TRADITIONAL DIAGNOSTIC TESTS 127
7.4.1 IMMUNODIAGNOSTICS 128
7.4.1.1 Rising demand for rapid disease diagnosis to fuel uptake 128
7.4.2 BIOCHEMICAL TESTS 129
7.4.2.1 Ability to accurately measure biomarkers in pneumonia and
bronchitis infections to boost demand 129
7.4.3 MICROSCOPY 131
7.4.3.1 Inadequate sensitivity towards emerging viruses to restrain market 131
7.5 MOLECULAR DIAGNOSTIC TESTS 132
7.5.1 POLYMERASE CHAIN REACTION (PCR) 133
7.5.1.1 Development of portable and real-time PCR machines to drive market 133
7.5.2 NUCLEIC ACID AMPLIFICATION TEST (NAAT) 134
7.5.2.1 Rapid identification of viral, bacterial, and fungal infections to fuel demand 134
7.5.3 IN SITU HYBRIDIZATION (ISH) 136
7.5.3.1 Utilization of probes for pathogen detection to support market growth 136
7.5.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS) 137
7.5.4.1 High-throughput capabilities for rapid analysis of genetic data
to propel market 137
7.5.5 MICROARRAYS 138
7.5.5.1 Detection of hepatitis C and respiratory viruses to support market growth 138
7.5.6 OTHER MOLECULAR DIAGNOSTIC TESTS 140
8 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE 141
8.1 INTRODUCTION 142
8.2 TUBERCULOSIS 142
8.2.1 FAVORABLE FUNDING INITIATIVES FOR TB TREATMENT TO DRIVE MARKET 142
8.3 ASTHMA 143
8.3.1 INCREASING AIR POLLUTION AND GROWING USE OF TOBACCO-BASED PRODUCTS TO DRIVE MARKET 143
8.4 LUNG CANCER 145
8.4.1 NON-SMALL-CELL LUNG CANCER (NSCLC) 146
8.4.1.1 Rising investments in advanced radiographic technologies to fuel market 146
8.4.2 SMALL-CELL LUNG CANCER (SCLC) 147
8.4.2.1 Growing emphasis on precision testing to drive market 147
8.4.3 OTHER LUNG CANCERS 148
8.5 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 149
8.5.1 ADVANCEMENTS IN SPIROMETRY AND PLETHYSMOGRAPHY FOR
COPD DIAGNOSIS TO FUEL MARKET 149
8.6 PNEUMONIA 151
8.6.1 RISING INCIDENCE OF RESPIRATORY INFECTIONS TO BOOST DEMAND 151
8.7 OTHER DISEASES 153
9 RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE 154
9.1 INTRODUCTION 155
9.2 SYNDROMIC DIAGNOSIS 155
9.2.1 DETECTION OF MULTIPLE PANELS OF VIRAL PATHOGENS TO PROPEL MARKET 155
9.3 ETIOLOGICAL DIAGNOSIS 156
9.3.1 IDENTIFICATION OF SPECIFIC CAUSE OF RESPIRATORY ILLNESSES TO FUEL MARKET 156
9.4 PROGNOSIS DIAGNOSIS 158
9.4.1 ASSESSMENT OF BIOMARKERS FOR DISEASE PROGRESSION TO SUPPORT MARKET GROWTH 158
?
10 RESPIRATORY DIAGNOSTICS MARKET, BY END USER 160
10.1 INTRODUCTION 161
10.2 HOSPITALS & CLINICS 161
10.2.1 GROWING ACCESSIBILITY TO ADVANCED EQUIPMENT TO FUEL MARKET 161
10.3 DIAGNOSTIC LABORATORIES 163
10.3.1 ABILITY TO PROVIDE AFFORDABLE TESTING PROCESSES WITH TIMELY RESULTS
TO BOOST DEMAND 163
10.4 LONG-TERM CARE & SPECIALTY CENTERS 164
10.4.1 PROVISION OF SPECIALIZED & ADVANCED SERVICES TO PROPEL MARKET 164
10.5 ACADEMIC & RESEARCH INSTITUTES 165
10.5.1 FAVORABLE FUNDING INITIATIVES TO SUPPORT MARKET GROWTH 165
11 RESPIRATORY DIAGNOSTICS MARKET, BY REGION 166
11.1 INTRODUCTION 167
11.2 NORTH AMERICA 168
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 168
11.2.2 US 174
11.2.2.1 Growing accessibility to technologically advanced products
to boost demand 174
11.2.3 CANADA 178
11.2.3.1 Rising incidence of COPD to drive market 178
11.3 EUROPE 183
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 183
11.3.2 GERMANY 188
11.3.2.1 Increasing public healthcare expenditure to foster market growth 188
11.3.3 UK 192
11.3.3.1 Rising establishment of hospitals and increasing number of surgical procedures to fuel market 192
11.3.4 FRANCE 197
11.3.4.1 High prevalence of smoking and increasing demand for respiratory
devices to drive market 197
11.3.5 ITALY 201
11.3.5.1 Unfavorable amendments to healthcare policies to restrain market 201
11.3.6 SPAIN 206
11.3.6.1 Increasing demand for home healthcare services to support market growth 206
11.3.7 REST OF EUROPE 210
11.4 ASIA PACIFIC 215
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 215
11.4.2 JAPAN 221
11.4.2.1 Availability of universal healthcare reimbursement policy to drive market 221
11.4.3 CHINA 225
11.4.3.1 High incidence of viral respiratory infections to propel market 225
?
11.4.4 INDIA 230
11.4.4.1 Expansion of leading medical device manufacturers and large target
patient population to drive market 230
11.4.5 AUSTRALIA 234
11.4.5.1 High prevalence of chronic lung diseases to boost demand 234
11.4.6 SOUTH KOREA 238
11.4.6.1 Expanding geriatric population and rising incidence of chronic
respiratory conditions to fuel market 238
11.4.7 REST OF ASIA PACIFIC 243
11.5 LATIN AMERICA 247
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 247
11.5.2 BRAZIL 251
11.5.2.1 Favorable government initiatives for healthcare sector improvement
to drive market 251
11.5.3 MEXICO 256
11.5.3.1 Rising prevalence of obesity & hypertension to fuel uptake 256
11.5.4 REST OF LATIN AMERICA 260
11.6 MIDDLE EAST & AFRICA 264
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 264
11.6.2 GCC COUNTRIES 269
11.6.2.1 Kingdom of Saudi Arabia (KSA) 273
11.6.2.1.1 Investments in advanced healthcare technologies to drive market 273
11.6.2.2 United Arab Emirates (UAE) 277
11.6.2.2.1 Rising prevalence of asthma to support market growth 277
11.6.2.3 Other GCC Countries 282
11.6.3 REST OF MIDDLE EAST & AFRICA 286
12 COMPETITIVE LANDSCAPE 290
12.1 INTRODUCTION 290
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2021–DECEMBER 2024 290
12.3 REVENUE ANALYSIS, 2019–2023 291
12.4 MARKET SHARE ANALYSIS, 2023 292
12.4.1 RANKING OF KEY MARKET PLAYERS 294
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 295
12.5.1 STARS 295
12.5.2 EMERGING LEADERS 295
12.5.3 PERVASIVE PLAYERS 295
12.5.4 PARTICIPANTS 295
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 297
12.5.5.1 Company footprint 297
12.5.5.2 Region footprint 298
12.5.5.3 Product & service footprint 299
12.5.5.4 Test type footprint 300
12.5.5.5 Disease type footprint 301
12.5.5.6 End-user footprint 302
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 303
12.6.1 PROGRESSIVE COMPANIES 303
12.6.2 RESPONSIVE COMPANIES 303
12.6.3 DYNAMIC COMPANIES 303
12.6.4 STARTING BLOCKS 303
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 305
12.7 BRAND/PRODUCT COMPARISON 307
12.8 R&D EXPENDITURE OF KEY PLAYERS 308
12.9 COMPANY VALUATION & FINANCIAL METRICS 308
12.9.1 FINANCIAL METRICS 308
12.9.2 COMPANY VALUATION 309
12.10 COMPETITIVE SCENARIO 309
12.10.1 PRODUCT & SERVICE LAUNCHES AND APPROVALS 309
12.10.2 DEALS 310
12.10.3 EXPANSIONS 311
12.10.4 OTHER DEVELOPMENTS 312
13 COMPANY PROFILES 313
13.1 KEY PLAYERS 313
13.1.1 KONINKLIJKE PHILIPS N.V. 313
13.1.1.1 Business overview 313
13.1.1.2 Products & services offered 314
13.1.1.3 Recent developments 316
13.1.1.3.1 Product launches 316
13.1.1.3.2 Deals 316
13.1.1.3.3 Expansions 317
13.1.1.4 MnM view 317
13.1.1.4.1 Key strengths 317
13.1.1.4.2 Strategic choices 318
13.1.1.4.3 Weaknesses & competitive threats 318
13.1.2 BECTON, DICKINSON AND COMPANY 319
13.1.2.1 Business overview 319
13.1.2.2 Products & services offered 321
13.1.2.3 Recent developments 322
13.1.2.3.1 Product launches & approvals 322
13.1.2.3.2 Deals 323
13.1.2.4 MnM view 324
13.1.2.4.1 Key strengths 324
13.1.2.4.2 Strategic choices 324
13.1.2.4.3 Weaknesses & competitive threats 324
13.1.3 ABBOTT LABORATORIES 325
13.1.3.1 Business overview 325
13.1.3.2 Products & services offered 326
13.1.3.3 Recent developments 327
13.1.3.3.1 Product approvals 327
13.1.3.4 MnM view 327
13.1.3.4.1 Key strengths 327
13.1.3.4.2 Strategic choices 327
13.1.3.4.3 Weaknesses & competitive threats 327
13.1.4 THERMO FISHER SCIENTIFIC INC. 328
13.1.4.1 Business overview 328
13.1.4.2 Products & services offered 329
13.1.4.3 Recent developments 331
13.1.4.3.1 Product & service launches 331
13.1.4.3.2 Deals 332
13.1.4.4 MnM view 332
13.1.4.4.1 Key strengths 332
13.1.4.4.2 Strategic choices 332
13.1.4.4.3 Weaknesses & competitive threats 332
13.1.5 GE HEALTHCARE TECHNOLOGIES, INC. 333
13.1.5.1 Business overview 333
13.1.5.2 Products & services offered 334
13.1.5.3 Recent developments 337
13.1.5.3.1 Product & service launches & approvals 337
13.1.5.3.2 Deals 338
13.1.5.3.3 Other developments 339
13.1.5.4 MnM view 340
13.1.5.4.1 Key strengths 340
13.1.5.4.2 Strategic choices 340
13.1.5.4.3 Weaknesses & competitive threats 340
13.1.6 BIO-RAD LABORATORIES, INC. 341
13.1.6.1 Business overview 341
13.1.6.2 Products & services offered 342
13.1.6.3 Recent developments 344
13.1.6.3.1 Product launches & approvals 344
13.1.6.3.2 Deals 345
13.1.7 BIOM?RIEUX 346
13.1.7.1 Business overview 346
13.1.7.2 Products & services offered 347
13.1.7.3 Recent developments 348
13.1.7.3.1 Product launches & approvals 348
13.1.7.3.2 Deals 348
13.1.8 REVVITY, INC. 349
13.1.8.1 Business overview 349
13.1.8.2 Products & services offered 350
13.1.8.3 Recent developments 352
13.1.8.3.1 Product launches & approvals 352
13.1.8.3.2 Deals 352
13.1.9 SEEGENE INC. 353
13.1.9.1 Business overview 353
13.1.9.2 Products & services offered 354
13.1.9.3 Recent developments 356
13.1.9.3.1 Product launches & approvals 356
13.1.9.3.2 Deals 356
13.1.9.3.3 Expansions 357
13.1.9.3.4 Other developments 357
13.1.10 NIHON KOHDEN CORPORATION 358
13.1.10.1 Business overview 358
13.1.10.2 Products & services offered 360
13.1.11 VITALOGRAPH 361
13.1.11.1 Business overview 361
13.1.11.2 Products & services offered 361
13.1.11.3 Recent developments 362
13.1.11.3.1 Product & service launches & approvals 362
13.1.11.3.2 Deals 363
13.1.12 SDI DIAGNOSTICS 364
13.1.12.1 Business overview 364
13.1.12.2 Products & services offered 365
13.1.13 RESMED INC. 366
13.1.13.1 Business overview 366
13.1.13.2 Products & services offered 367
13.1.13.3 Recent developments 368
13.1.13.3.1 Deals 368
13.1.13.3.2 Expansions 368
13.1.13.3.3 Other developments 368
13.1.14 SIEMENS HEALTHINEERS AG 369
13.1.14.1 Business overview 369
13.1.14.2 Products & services offered 370
13.1.14.3 Recent developments 372
13.1.14.3.1 Product launches 372
13.1.14.3.2 Deals 372
13.1.14.3.3 Expansions 373
?
13.1.15 COSMED SRL 374
13.1.15.1 Business overview 374
13.1.15.2 Products & services offered 374
13.1.15.3 Recent developments 375
13.1.15.3.1 Product launches 375
13.1.15.3.2 Deals 375
13.1.16 HOLOGIC, INC. 376
13.1.16.1 Business overview 376
13.1.16.2 Products & services offered 378
13.1.16.3 Recent developments 379
13.1.16.3.1 Product launches 379
13.1.16.3.2 Deals 379
13.1.17 QIAGEN N.V. 380
13.1.17.1 Business overview 380
13.1.17.2 Products & services offered 381
13.1.17.3 Recent developments 383
13.1.17.3.1 Product launches 383
13.1.17.3.2 Deals 384
13.1.17.3.3 Other developments 384
13.2 OTHER PLAYERS 385
13.2.1 MGC DIAGNOSTICS CORPORATION 385
13.2.2 VISBY MEDICAL, INC. 386
13.2.3 BRIOTA TECHNOLOGIES PVT. LTD. 386
13.2.4 BIRD HEALTHCARE 387
13.2.5 L?WENSTEIN MEDICAL SE & CO. KG 388
13.2.6 PROAXSIS 388
13.2.7 NDD MEDICAL TECHNOLOGIES 389
13.2.8 COMPUMEDICS LIMITED 390
14 APPENDIX 391
14.1 DISCUSSION GUIDE 391
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS? SUBSCRIPTION PORTAL 400
14.3 CUSTOMIZATION OPTIONS 402
14.4 RELATED REPORTS 402
14.5 AUTHOR DETAILS 403



List of Figures

FIGURE 1 RESPIRATORY DIAGNOSTICS MARKET: MARKET & REGIONAL SPREAD 34
FIGURE 2 RESPIRATORY DIAGNOSTICS MARKET: YEARS CONSIDERED 35
FIGURE 3 RESEARCH DESIGN 38
FIGURE 4 RESPIRATORY DIAGNOSTICS MARKET: KEY PRIMARY SOURCES 40
FIGURE 5 RESPIRATORY DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES 41
FIGURE 6 RESPIRATORY DIAGNOSTICS MARKET: KEY INDUSTRY INSIGHTS 42
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 42
FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 43
FIGURE 9 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE):
BY END USER, DESIGNATION, AND REGION 43
FIGURE 10 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 44
FIGURE 11 REVENUE SHARE ANALYSIS ILLUSTRATION: KONINKLIJKE PHILIPS N.V. (2023) 45
FIGURE 12 SUPPLY-SIDE ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET (2023) 46
FIGURE 13 RESPIRATORY DIAGNOSTICS MARKET: TOP-DOWN APPROACH 47
FIGURE 14 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS OPPORTUNITIES, AND CHALLENGES 48
FIGURE 15 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 48
FIGURE 16 RESPIRATORY DIAGNOSTICS MARKET: DATA TRIANGULATION METHODOLOGY 49
FIGURE 17 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 2024 VS. 2030 (USD MILLION) 52
FIGURE 18 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2024 VS. 2030 (USD MILLION) 53
FIGURE 19 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2024 VS. 2030 (USD MILLION) 53
FIGURE 20 RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE 2024 VS. 2030 (USD MILLION) 54
FIGURE 21 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2030 (USD MILLION) 54
FIGURE 22 GEOGRAPHIC SNAPSHOT OF RESPIRATORY DIAGNOSTICS MARKET 55
FIGURE 23 RISING PREVALENCE OF RESPIRATORY DISEASES TO PROPEL MARKET 56
FIGURE 24 INSTRUMENTS & DEVICES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE
IN CHINA (2023) 57
FIGURE 25 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 58
FIGURE 26 INDIA TO GROW AT HIGHEST GROWTH RATE DURING FORECAST PERIOD 58
FIGURE 27 RESPIRATORY DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES 59
FIGURE 28 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) DALY FOR INDIVIDUALS
IN AUSTRALIA, BY AGE (2023) 60
FIGURE 29 GLOBAL GERIATRIC POPULATION, BY REGION 61
FIGURE 30 RESPIRATORY DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 70
FIGURE 31 NUMBER OF PATENTS PUBLISHED, JANUARY 2014–DECEMBER 2024 80
FIGURE 32 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR RESPIRATORY DIAGNOSTICS DEVICES (JANUARY 2014– DECEMBER 2024) 80
FIGURE 33 TOP PATENT APPLICANTS, BY JURISDICTION, JANUARY 2014?DECEMBER 2024 81
FIGURE 34 AVERAGE SELLING PRICE OF SPIROMETERS, BY KEY PLAYER (2024) 84
FIGURE 35 AVERAGE SELLING PRICE OF PEAK FLOWMETERS, BY KEY PLAYER (2024) 84
FIGURE 36 RESPIRATORY DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS 86
FIGURE 37 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESPIRATORY
DIAGNOSTIC DEVICES 87
FIGURE 38 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES 88
FIGURE 39 RESPIRATORY DIAGNOSTICS MARKET: ADJACENT MARKETS 90
FIGURE 40 RESPIRATORY DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 91
FIGURE 41 RESPIRATORY DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 95
FIGURE 42 RESPIRATORY DIAGNOSTICS MARKET: TRENDS/DISRUPTIONS IMPACTING
CUSTOMERS’ BUSINESSES 96
FIGURE 43 RESPIRATORY DIAGNOSTICS MARKET: NUMBER OF DEALS, 2020–2024 97
FIGURE 44 RESPIRATORY DIAGNOSTICS MARKET: IMPACT OF AI/GEN AI 99
FIGURE 45 RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT 167
FIGURE 46 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT 169
FIGURE 47 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT 216
FIGURE 48 RESPIRATORY DIAGNOSTICS MARKET: REVENUE ANALYSIS
OF KEY PLAYERS, 2019?2023 292
FIGURE 49 MARKET SHARE ANALYSIS OF KEY PLAYERS IN RESPIRATORY
DIAGNOSTICS MARKET (2023) 293
FIGURE 50 RANKING OF KEY PLAYERS IN RESPIRATORY DIAGNOSTICS MARKET, 2023 294
FIGURE 51 RESPIRATORY DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 296
FIGURE 52 RESPIRATORY DIAGNOSTICS MARKET: COMPANY FOOTPRINT 297
FIGURE 53 RESPIRATORY DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 304
FIGURE 54 RESPIRATORY DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 307
FIGURE 55 R&D EXPENDITURE OF KEY PLAYERS IN RESPIRATORY DIAGNOSTICS
MARKET, 2022?2024 308
FIGURE 56 EV/EBITDA OF KEY VENDORS 308
FIGURE 57 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 309
FIGURE 58 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023) 314
FIGURE 59 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2024) 320
FIGURE 60 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2023) 326
FIGURE 61 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 329
FIGURE 62 GE HEALTHCARE TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023) 334
FIGURE 63 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023) 342
FIGURE 64 BIOM?RIEUX: COMPANY SNAPSHOT (2023) 347
FIGURE 65 REVVITY, INC.: COMPANY SNAPSHOT (2023) 350
FIGURE 66 SEEGENE INC.: COMPANY SNAPSHOT (2023) 353
FIGURE 67 NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT (2023) 359
FIGURE 68 RESMED INC.: COMPANY SNAPSHOT (2024) 367
FIGURE 69 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024) 370
FIGURE 70 HOLOGIC, INC.: COMPANY SNAPSHOT (2024) 377
FIGURE 71 QIAGEN N.V.: COMPANY SNAPSHOT (2023) 381

List of Tables

TABLE 1 RESPIRATORY DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS 35
TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 36
TABLE 3 RESPIRATORY DIAGNOSTICS MARKET: STUDY ASSUMPTIONS 50
TABLE 4 RESPIRATORY DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS 51
TABLE 5 AWARENESS INITIATIVES ON EFFECTS OF UNTREATED SLEEP APNEA 65
TABLE 6 RESPIRATORY DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 70
TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 72
TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 74
TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 75
TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 75
TABLE 12 US: CLASSIFICATION OF MEDICAL EQUIPMENT 75
TABLE 13 US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 76
TABLE 14 CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 76
TABLE 15 EUROPE: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 77
TABLE 16 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 78
TABLE 17 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 78
TABLE 18 RESPIRATORY DIAGNOSTICS MARKET: INNOVATIONS AND PATENT
REGISTRATIONS, 2022?2024 81
TABLE 19 IMPORT DATA FOR HS CODE 901819, BY COUNTRY, 2019–2023 (USD THOUSAND) 82
TABLE 20 EXPORT DATA FOR HS CODE 901819, BY COUNTRY, 2019–2023 (USD THOUSAND) 83
TABLE 21 AVERAGE SELLING PRICE TREND OF RESPIRATORY DIAGNOSTIC PRODUCTS BY REGION, 2021–2023 (USD) 85
TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESPIRATORY
DIAGNOSTIC DEVICES 87
TABLE 23 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES 88
TABLE 24 RESPIRATORY DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2024?2025 89
TABLE 25 RESPIRATORY DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM 92
TABLE 26 CASE STUDY 1: ACUPEBBLE SA100 – TRANSFORMING SLEEP APNEA DIAGNOSIS 93
TABLE 27 CASE STUDY 2: REMOTE MONITORING SOLUTION FOR COVID-19 PATIENTS IN INDONESIA 93
TABLE 28 CASE STUDY 3: EFFECTIVE MANAGEMENT OF A 71-YEAR-OLD COPD PATIENT
WITH ACUTE EXACERBATIONS 94
TABLE 29 RESPIRATORY DIAGNOSTICS MARKET: REIMBURSEMENT SCENARIO 97
TABLE 30 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 2022–2030 (USD MILLION) 101
TABLE 31 RESPIRATORY DIAGNOSTICS MARKET FOR INSTRUMENTS & DEVICES BY COUNTRY, 2022–2030 (USD MILLION) 102
TABLE 32 RESPIRATORY DIAGNOSTICS MARKET FOR ASSAYS & REAGENTS BY COUNTRY, 2022–2030 (USD MILLION) 104
TABLE 33 RESPIRATORY DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE BY COUNTRY, 2022–2030 (USD MILLION) 105
TABLE 34 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 107
TABLE 35 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS BY COUNTRY, 2022–2030 (USD MILLION) 108
TABLE 36 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS BY TYPE, 2022–2030 (USD MILLION) 109
TABLE 37 RESPIRATORY DIAGNOSTICS MARKET FOR PULMONARY FUNCTION TESTS BY COUNTRY, 2022–2030 (USD MILLION) 110
TABLE 38 RESPIRATORY DIAGNOSTICS MARKET FOR PULMONARY FUNCTION TESTS BY TYPE, 2022–2030 (USD MILLION) 111
TABLE 39 SPIROMETRY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 112
TABLE 40 SPIROMETRY TESTS MARKET, BY REGION, 2022–2030 (THOUSAND UNITS) 113
TABLE 41 PEAK FLOW TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 114
TABLE 42 PEAK FLOW TESTS MARKET, BY REGION, 2022–2030 (THOUSAND UNITS) 115
TABLE 43 OTHER PULMONARY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 116
TABLE 44 OTHER PULMONARY TESTS MARKET, BY REGION, 2022–2030 (THOUSAND UNITS) 117
TABLE 45 OBSTRUCTIVE SLEEP APNEA DIAGNOSTIC TESTS MARKET BY COUNTRY, 2022–2030 (USD MILLION) 118
TABLE 46 OTHER MECHANICAL TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 119
TABLE 47 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS BY COUNTRY, 2022–2030 (USD MILLION) 120
TABLE 48 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS BY TYPE, 2022–2030 (USD MILLION) 121
TABLE 49 X-RAY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 122
TABLE 50 COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 123
TABLE 51 MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 124
TABLE 52 POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 125
TABLE 53 OTHER IMAGING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 126
TABLE 54 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS BY COUNTRY, 2022–2030 (USD MILLION) 127
TABLE 55 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS BY TYPE, 2022–2030 (USD MILLION) 128
TABLE 56 IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 129
TABLE 57 BIOCHEMICAL TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 130
TABLE 58 MICROSCOPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 131
TABLE 59 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS BY COUNTRY, 2022–2030 (USD MILLION) 132
TABLE 60 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS BY TYPE, 2022–2030 (USD MILLION) 133
TABLE 61 PCR MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 134
TABLE 62 NUCLEIC ACID AMPLIFICATION TEST MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 135
TABLE 63 IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 136
TABLE 64 DNA SEQUENCING & NEXT-GENERATION SEQUENCING MARKET BY COUNTRY, 2022–2030 (USD MILLION) 138
TABLE 65 MICROARRAYS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 139
TABLE 66 OTHER MOLECULAR DIAGNOSTIC TESTS MARKET BY COUNTRY, 2022–2030 (USD MILLION) 140
TABLE 67 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 142
TABLE 68 RESPIRATORY DIAGNOSTICS MARKET FOR TUBERCULOSIS BY COUNTRY, 2022–2030 (USD MILLION) 143
TABLE 69 RESPIRATORY DIAGNOSTICS MARKET FOR ASTHMA BY COUNTRY, 2022–2030 (USD MILLION) 144
TABLE 70 RESPIRATORY DIAGNOSTICS MARKET FOR LUNG CANCER BY COUNTRY, 2022–2030 (USD MILLION) 145
TABLE 71 RESPIRATORY DIAGNOSTICS MARKET FOR LUNG CANCER BY TYPE, 2022–2030 (USD MILLION) 146
TABLE 72 NON-SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 147
TABLE 73 SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 148
TABLE 74 OTHER LUNG CANCERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 149
TABLE 75 RESPIRATORY DIAGNOSTICS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2022–2030 (USD MILLION) 150
TABLE 76 RESPIRATORY DIAGNOSTICS MARKET FOR PNEUMONIA BY COUNTRY, 2022–2030 (USD MILLION) 152
TABLE 77 RESPIRATORY DIAGNOSTICS MARKET FOR OTHER DISEASES BY COUNTRY, 2022–2030 (USD MILLION) 153
TABLE 78 RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 155
TABLE 79 SYNDROMIC DIAGNOSIS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 156
TABLE 80 ETIOLOGICAL DIAGNOSIS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 157
TABLE 81 PROGNOSIS DIAGNOSIS MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 159
TABLE 82 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 161
TABLE 83 RESPIRATORY DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS BY COUNTRY, 2022–2030 (USD MILLION) 162
TABLE 84 RESPIRATORY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES BY COUNTRY, 2022–2030 (USD MILLION) 163
TABLE 85 RESPIRATORY DIAGNOSTICS MARKET FOR LONG-TERM CARE & SPECIALTY CENTERS BY COUNTRY, 2022–2030 (USD MILLION) 164
TABLE 86 RESPIRATORY DIAGNOSTICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES BY COUNTRY, 2022–2030 (USD MILLION) 165
TABLE 87 RESPIRATORY DIAGNOSTICS MARKET, BY REGION, 2022–2030 (USD MILLION) 168
TABLE 88 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET BY COUNTRY, 2022–2030 (USD MILLION) 170
TABLE 89 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 170
TABLE 90 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET BY TEST TYPE, 2022–2030 (USD MILLION) 170
TABLE 91 NORTH AMERICA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 171
TABLE 92 NORTH AMERICA: PULMONARY FUNCTION TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 171
TABLE 93 NORTH AMERICA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 171
TABLE 94 NORTH AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 172
TABLE 95 NORTH AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 172
TABLE 96 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET BY DISEASE TYPE, 2022–2030 (USD MILLION) 172
TABLE 97 NORTH AMERICA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 173
TABLE 98 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 173
TABLE 99 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET BY END USER, 2022–2030 (USD MILLION) 173
TABLE 100 US: KEY MACROINDICATORS 174
TABLE 101 US: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 2022–2030 (USD MILLION) 175
TABLE 102 US: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 175
TABLE 103 US: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 175
TABLE 104 US: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 176
TABLE 105 US: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 176
TABLE 106 US: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 176
TABLE 107 US: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 177
TABLE 108 US: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 177
TABLE 109 US: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 177
TABLE 110 US: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE 2022–2030 (USD MILLION) 178
TABLE 111 US: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 178
TABLE 112 CANADA: KEY MACROINDICATORS 179
TABLE 113 CANADA: RESPIRATORY DIAGNOSTICS MARKET BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 179
TABLE 114 CANADA: RESPIRATORY DIAGNOSTICS MARKET BY TEST TYPE, 2022–2030 (USD MILLION) 179
TABLE 115 CANADA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 180
TABLE 116 CANADA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 180
TABLE 117 CANADA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 180
TABLE 118 CANADA: TRADITIONAL DIAGNOSTIC TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 181
TABLE 119 CANADA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 181
TABLE 120 CANADA: RESPIRATORY DIAGNOSTICS MARKET BY DISEASE TYPE, 2022–2030 (USD MILLION) 181
TABLE 121 CANADA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 182
TABLE 122 CANADA: RESPIRATORY DIAGNOSTICS MARKET BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 182
TABLE 123 CANADA: RESPIRATORY DIAGNOSTICS MARKET BY END USER, 2022–2030 (USD MILLION) 182
TABLE 124 EUROPE: RESPIRATORY DIAGNOSTICS MARKET BY COUNTRY, 2022–2030 (USD MILLION) 184
TABLE 125 EUROPE: RESPIRATORY DIAGNOSTICS MARKET BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 184
TABLE 126 EUROPE: RESPIRATORY DIAGNOSTICS MARKET BY TEST TYPE, 2022–2030 (USD MILLION) 184
TABLE 127 EUROPE: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 185
TABLE 128 EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 185
TABLE 129 EUROPE: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 185
TABLE 130 EUROPE: TRADITIONAL DIAGNOSTIC TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 186
TABLE 131 EUROPE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 186
TABLE 132 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE 2022–2030 (USD MILLION) 186
TABLE 133 EUROPE: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 187
TABLE 134 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE 2022–2030 (USD MILLION) 187
TABLE 135 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER 2022–2030 (USD MILLION) 187
TABLE 136 GERMANY: KEY MACROINDICATORS 188
TABLE 137 GERMANY: RESPIRATORY DIAGNOSTICS MARKET BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 188
TABLE 138 GERMANY: RESPIRATORY DIAGNOSTICS MARKET BY TEST TYPE, 2022–2030 (USD MILLION) 189
TABLE 139 GERMANY: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 189
TABLE 140 GERMANY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 189
TABLE 141 GERMANY: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 190
TABLE 142 GERMANY: TRADITIONAL DIAGNOSTIC TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 190
TABLE 143 GERMANY: MOLECULAR DIAGNOSTIC TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 190
TABLE 144 GERMANY: RESPIRATORY DIAGNOSTICS MARKET BY DISEASE TYPE, 2022–2030 (USD MILLION) 191
TABLE 145 GERMANY: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 191
TABLE 146 GERMANY: RESPIRATORY DIAGNOSTICS MARKET BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 191
TABLE 147 GERMANY: RESPIRATORY DIAGNOSTICS MARKET BY END USER, 2022–2030 (USD MILLION) 192
TABLE 148 UK: KEY MACROINDICATORS 193
TABLE 149 UK: RESPIRATORY DIAGNOSTICS MARKET BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 193
TABLE 150 UK: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 193
TABLE 151 UK: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 194
TABLE 152 UK: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 194
TABLE 153 UK: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 194
TABLE 154 UK: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 195
TABLE 155 UK: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 195
TABLE 156 UK: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION) 195
TABLE 157 UK: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 196
TABLE 158 UK: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE 2022–2030 (USD MILLION) 196
TABLE 159 UK: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 196
TABLE 160 FRANCE: KEY MACROINDICATORS 197
TABLE 161 FRANCE: RESPIRATORY DIAGNOSTICS MARKET BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 197
TABLE 162 FRANCE: RESPIRATORY DIAGNOSTICS MARKET BY TEST TYPE, 2022–2030 (USD MILLION) 198
TABLE 163 FRANCE: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 198
TABLE 164 FRANCE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 198
TABLE 165 FRANCE: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 199
TABLE 166 FRANCE: TRADITIONAL DIAGNOSTIC TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 199
TABLE 167 FRANCE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 199
TABLE 168 FRANCE: RESPIRATORY DIAGNOSTICS MARKET BY DISEASE TYPE, 2022–2030 (USD MILLION) 200
TABLE 169 FRANCE: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 200
TABLE 170 FRANCE: RESPIRATORY DIAGNOSTICS MARKET BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 200
TABLE 171 FRANCE: RESPIRATORY DIAGNOSTICS MARKET BY END USER, 2022–2030 (USD MILLION) 201
TABLE 172 ITALY: KEY MACROINDICATORS 202
TABLE 173 ITALY: RESPIRATORY DIAGNOSTICS MARKET BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 202
TABLE 174 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 202
TABLE 175 ITALY: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 203
TABLE 176 ITALY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 203
TABLE 177 ITALY: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 203
TABLE 178 ITALY: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 204
TABLE 179 ITALY: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 204
TABLE 180 ITALY: RESPIRATORY DIAGNOSTICS MARKET BY DISEASE TYPE, 2022–2030 (USD MILLION) 204
TABLE 181 ITALY: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 205
TABLE 182 ITALY: RESPIRATORY DIAGNOSTICS MARKET BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 205
TABLE 183 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 205
TABLE 184 SPAIN: KEY MACROINDICATORS 206
TABLE 185 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 2022–2030 (USD MILLION) 207
TABLE 186 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 207
TABLE 187 SPAIN: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 207
TABLE 188 SPAIN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 208
TABLE 189 SPAIN: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 208
TABLE 190 SPAIN: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 208
TABLE 191 SPAIN: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 209
TABLE 192 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE 2022–2030 (USD MILLION) 209
TABLE 193 SPAIN: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 209
TABLE 194 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE 2022–2030 (USD MILLION) 210
TABLE 195 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 210
TABLE 196 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 211
TABLE 197 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET BY TEST TYPE, 2022–2030 (USD MILLION) 211
TABLE 198 REST OF EUROPE: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 211
TABLE 199 REST OF EUROPE: PULMONARY FUNCTION TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 212
TABLE 200 REST OF EUROPE: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 212
TABLE 201 REST OF EUROPE: TRADITIONAL DIAGNOSTIC TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 212
TABLE 202 REST OF EUROPE: MOLECULAR DIAGNOSTIC TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 213
TABLE 203 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET BY DISEASE TYPE, 2022–2030 (USD MILLION) 213
TABLE 204 REST OF EUROPE: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 213
TABLE 205 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 214
TABLE 206 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET BY END USER, 2022–2030 (USD MILLION) 214
TABLE 207 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET BY COUNTRY, 2022–2030 (USD MILLION) 217
TABLE 208 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 217
TABLE 209 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET BY TEST TYPE, 2022–2030 (USD MILLION) 217
TABLE 210 ASIA PACIFIC: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 218
TABLE 211 ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 218
TABLE 212 ASIA PACIFIC: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 218
TABLE 213 ASIA PACIFIC: TRADITIONAL DIAGNOSTIC TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 219
TABLE 214 ASIA PACIFIC: MOLECULAR DIAGNOSTIC TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 219
TABLE 215 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET BY DISEASE TYPE, 2022–2030 (USD MILLION) 219
TABLE 216 ASIA PACIFIC: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 220
TABLE 217 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 220
TABLE 218 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET BY END USER, 2022–2030 (USD MILLION) 220
TABLE 219 JAPAN: KEY MACROINDICATORS 221
TABLE 220 JAPAN: RESPIRATORY DIAGNOSTICS MARKET BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 221
TABLE 221 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 222
TABLE 222 JAPAN: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 222
TABLE 223 JAPAN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 222
TABLE 224 JAPAN: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 223
TABLE 225 JAPAN: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 223
TABLE 226 JAPAN: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 223
TABLE 227 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE 2022–2030 (USD MILLION) 224
TABLE 228 JAPAN: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 224
TABLE 229 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE 2022–2030 (USD MILLION) 224
TABLE 230 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION) 225
TABLE 231 CHINA: KEY MACROINDICATORS 226
TABLE 232 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 2022–2030 (USD MILLION) 226
TABLE 233 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 226
TABLE 234 CHINA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 227
TABLE 235 CHINA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 227
TABLE 236 CHINA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 227
TABLE 237 CHINA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 228
TABLE 238 CHINA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 228
TABLE 239 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE 2022–2030 (USD MILLION) 228
TABLE 240 CHINA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 229
TABLE 241 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE 2022–2030 (USD MILLION) 229
TABLE 242 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER 2022–2030 (USD MILLION) 229
TABLE 243 INDIA: KEY MACROINDICATORS 230
TABLE 244 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 2022–2030 (USD MILLION) 230
TABLE 245 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION) 231
TABLE 246 INDIA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 231
TABLE 247 INDIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 231
TABLE 248 INDIA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 232
TABLE 249 INDIA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 232
TABLE 250 INDIA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 232
TABLE 251 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE 2022–2030 (USD MILLION) 233
TABLE 252 INDIA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 233
TABLE 253 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE 2022–2030 (USD MILLION) 233
TABLE 254 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER 2022–2030 (USD MILLION) 234
TABLE 255 AUSTRALIA: KEY MACROINDICATORS 234
TABLE 256 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 235
TABLE 257 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET BY TEST TYPE, 2022–2030 (USD MILLION) 235
TABLE 258 AUSTRALIA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 235
TABLE 259 AUSTRALIA: PULMONARY FUNCTION TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 236
TABLE 260 AUSTRALIA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 236
TABLE 261 AUSTRALIA: TRADITIONAL DIAGNOSTIC TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 236
TABLE 262 AUSTRALIA: MOLECULAR DIAGNOSTIC TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 237
TABLE 263 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET BY DISEASE TYPE, 2022–2030 (USD MILLION) 237
TABLE 264 AUSTRALIA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 237
TABLE 265 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 238
TABLE 266 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET BY END USER, 2022–2030 (USD MILLION) 238
TABLE 267 SOUTH KOREA: KEY MACROINDICATORS 239
TABLE 268 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 239
TABLE 269 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET BY TEST TYPE, 2022–2030 (USD MILLION) 239
TABLE 270 SOUTH KOREA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 240
TABLE 271 SOUTH KOREA: PULMONARY FUNCTION TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 240
TABLE 272 SOUTH KOREA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 240
TABLE 273 SOUTH KOREA: TRADITIONAL DIAGNOSTIC TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 241
TABLE 274 SOUTH KOREA: MOLECULAR DIAGNOSTIC TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 241
TABLE 275 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET BY DISEASE TYPE, 2022–2030 (USD MILLION) 241
TABLE 276 SOUTH KOREA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION) 242
TABLE 277 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION) 242
TABLE 278 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET BY END USER, 2022–2030 (USD MILLION) 242
TABLE 279 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET BY PRODUCT & SERVICE, 2022–2030 (USD MILLION) 243
TABLE 280 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET BY TEST TYPE, 2022–2030 (USD MILLION) 243
TABLE 281 REST OF ASIA PACIFIC: MECHANICAL TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 244
TABLE 282 REST OF ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 244
TABLE 283 REST OF ASIA PACIFIC: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION) 244
TABLE 284 REST OF ASIA PACIFIC: TRADITIONAL DIAGNOSTIC TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 245
TABLE 285 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTIC TESTS MARKET BY TYPE, 2022–2030 (USD MILLION) 245
TABLE 286 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET BY DISEASE TYPE, 2022–2030